RegMed Investors (RMi) Closing Bell: Econ’s inflation data was hotter than expected as May PCE pushes rate cuts odds lower

June 27, 2025 4:58pm

Yet again, we have to give-back on share pricing flicking’ the switch on share pricing issues, as trade talks end with Canada

Breadth was negative, with an advance/decline line of 10-to-21 on my covered Nasdaq listings; I'll be cautious cherry-picking exposure

Remain cautious, with your portfolio tilted toward cash

When you want to decant or fill your portfolio carafe, always consider it, a glass half-full

TGIF

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key sector-moving events and distill that into a cogent outlook.

Friday’s RegMed Investors’ (RMi) pre-open: Another econ, PCE … https://www.regmedinvestors.com/articles/13977

Thursday night’s RegMed Investors (RMi) Closing Bell: Econs cried havoc and let slip the algo dogs of electronic trading … https://www.regmedinvestors.com/articles/13976

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

Friday: The Dow closed UP +432.43 points or +1%, the S&P closed UP +32.05 points or +0.52% while the Nasdaq closed UP +105.54 points or +0.52%

• Theme of the session, feeling the gain overcoming by Canadian trade angst as my sector suffers inertia

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

• https://www.regmedinvestors.com/articles/13977

Friday’s advance/decline line opened barely positive with 16 incliners, 14 decliners and 5 flats ending with a negative close of 10 incliners, 21 decliners and 4 flats  

Metrics:  Friday, the IBB was down -0.54%, the XBI was down -0.81% while the VIX was down -0.13 points or -0.78% at 16.46

Q2/25 – June – 1 market holiday, 1 neutral, 9 negative and 10 positive closes

• May – 1 market holiday, 10 negative and 11 positive closes
• April – 11 positive and 10 negative closes

Friday Closing UP (10 of 10)

• Alnylam Pharmaceuticals (ALNY +$4.58 after Thursday’s -$3.69, Wednesday’s -$3.06, Tuesday’s +$11.87 and Monday’s +$3.43),
• CRISPR Therapeutics (CRSP +$0.79 after Thursday’s -$0.96, Wednesday’s +$0.88, Tuesday’s +$1.23 and Monday’s +$1.30),
• Mesoblast (MESO +$0.17 after Thursday’s +$0.20 and Wednesday’s +$0.10),
• Editas Medicine (EDIT +$0.16),
• Lenz Therapeutics (LENZ +$0.07 after Thursday’s +$0.59, Wednesday’s -$0.26, Tuesday’s -$0.77 and Monday’s +$0.54),
• Vericel (VCEL +$0.07 after Thursday’s -$0.22, Wednesday’s -$1.46, Tuesday’s +$1.54 and Monday’s -$0.22),
• Verve Therapeutics (VERV +$0.05),
• AxoGen (AXGN +$ after Thursday’s +$0.22, Wednesday’s +$0.11, Tuesday’s +$0.36 and Monday’s +$0.06)
• Ionis Pharmaceuticals (IONS +$0.02 after Thursday’s -$0.22, Wednesday’s +$0.36, Tuesday’s +$1.97 and Monday’s +$0.26),
• BioLife Solutions (BLFS +$0.01 after Thursday’s +$0.11, Wednesday’s -$0.43, Tuesday’s +$0.44 and Monday’s +$0.14),

Flat (4)

• bluebird bio (BLUE) P/E acquired
• Harvard Apparatus RT (OTCQB: HRGN)
• Homology Medicine (FIXX)
• MiMedx (MDXG)

Friday’s Closing DOWN (10 of 21):

• Ultragenyx Pharmaceuticals (RARE -$0.60 after Thursday’s -$0.31 and Wednesday’s +$0.27),
• Moderna (MRNA -$0.38 after Thursday’s +$0.68, Wednesday’s +$0.06, Tuesday’s +$1.13 and Monday’s -$0.26),
• uniQure NV (QURE -$0.37)
• Regenxbio (RGNX -$0.36 after Thursday’s +$0.21),
• Beam Therapeutics (BEAM -$0.34 after Thursday’s +$0.38, Wednesday’s -$0.39, Tuesday’s +$0.44 and Monday’s -$0.05),
• Prime Medicine (PRME -$0.23 after Thursday’s +$0.23),
• Adverum Biotechnologies (ADVM -$0.17 after Thursday’s -$0.09 and Wednesday’s +$0.04)
• Agenus (AGEN -$0.15),
• Sage Therapeutics (SAGE -$0.13),
• Solid Biosciences (SLDB -$0.09 after Thursday’s +$0.07, Wednesday’s -$0.115, Tuesday’s +$0.34 and Monday’s -$0.28),

The BOTTOM LINE:  Small caps on the Russell 2000 index reversed lower 0.4% and surrendered a position above the 2,200 level. Amid afternoon weakness, the Russell also tested its 200-day moving average. <IBD>

• In afternoon action, the 10-year Treasury yield climbed to around 4.28%. Oil prices ticked up to around $65.50 a barrel. And bitcoin dipped to over the $106,500 level. <IBD>

A new week <6/23 to 6/27> opens with a barely Monday negative close followed by a Tuesday positive close and a barely negative close on Wednesday and Thursday… followed by another down-turn in negative territory on Friday

This week, 6/16 – 6/20 started with a Monday positive close … followed by Tuesday’s negative close … and a Wednesday’s positive close, Thursday’s market holiday and Friday’s negative close.

• The week of 6/9 – 6/13; Friday, the cell and gene therapy sector stayed in negative territory following Thursday's trading session ended with a negative territory, after May's Producer Price Index (PPI) report following Wednesday's negative close after May's Consumer Price Index (CPI) report post Monday’s neutral close.
• The cell and gene therapy sector popped Friday after Thursday’s reverses on Thursday from a negative open with a barely positive close after Wednesday’s positive close – although slipping
• Following upsides on Tuesday and Monday) after its “napping and waking” in the May share pricing doldrums initiated by a sweetener of BPMC getting an acquired by BMY, MRNA regulatory approval and BNTX’s partnership with BMY.

As I also wrote, about June… Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

• Although historically, June (in the past) has been a slow or weak month – I/we just saw a tremendous start (6/2) with partnership, acquisition and regulatory news 
• Also, ASCO opens this month with probably a lot of news flow attracting attention of funds such as hedges and electronic traders.

There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

June ‘25: understand the “flow” …

• 6/27 – Friday closed negative with 10 positive, 21 negative and 4 flats
• 6/26 - Thursday closed negative with 14 positive, 18 negative and 3 flats
• 6/25 - Wednesday closed negative with 14 positive, 17 negative and 4 flats
• 6/24 - Tuesday closed positive with 30 positive, 3 negative and 2 flats
• 6/23 - Monday closed negative with 15 positive, 16 negative and 4 flats

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

• If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

• Friday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Mesoblast (MESO)
• Thursday:  Moderna (MRNA), Lenz Therapeutics (LENZ) and Beam Therapeutics (BEAM)
• Wednesday: CRISPR Therapeutics (CRSP), Ionis Pharmaceuticals (IONS) and Ultragenyx Pharmaceuticals (RARE)
• Tuesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Vericel (VCEL)
• Monday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and CRISPR Therapeutics (CRSP)
• Last Friday: Moderna (MRNA), AxoGen (AXGN) and

The worst three (3) in the session: 

• Friday: Ultragenyx Pharmaceuticals (RARE), Moderna (MRNA) and UniQure NV (QURE)
• Thursday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Ultragenyx Pharmaceuticals (RARE)
• Wednesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and BioLife Solutions (BLFS)
• Tuesday: Lenz Therapeutics (LENZ), Blueprint Medicine (BPMC) and Sage Therapeutics (SAGE)
• Monday: Vericel (VCEL), Regenxbio (RGNX) and Ultragenyx Pharmaceuticals (RARE)
• Last Friday: Mesoblast (MESO), uniQure NV (QURE) and Alnylam Pharmaceuticals (ALNY)

Welcome to my world of defining the “grey’ in our universe!

• Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.